US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

3.70

-0.4700-11.27%

Post-market: 3.700.00000.00%19:55 EDT

Volume:46.10K

Turnover:175.97K

Market Cap:3.58M

PE:-0.02

High:4.35

Open:4.28

Low:3.50

Close:4.17

52wk High:196.80

52wk Low:3.25

Shares:968.60K

Float Shares:697.36K

Volume Ratio:2.15

T/O Rate:6.61%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-190.7554

EPS(LYR):-1,128.6039

ROE:-2095.51%

ROA:-85.59%

PB:-1.78

PE(LYR):0.00

Loading ...

Overview Company News Filings

Super League Enterprise Raises $20 Million in Private Placement

Super League Enterprise Inc. Publishes Transcript of Third Quarter 2025 Earnings Conference Call

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

Super League Enterprise Q3 Adj. EPS $(2.52) Beats $(2.79) Estimate, Sales $2.423M Miss $3.395M Estimate

Super League Enterprise Reports Financial Turnaround and Restores Nasdaq Compliance

Super League Enterprise Inc - Q3 Revenues Decline to $2.4 Mln

THOMSON REUTERS

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Aegis Capital Initiates Coverage on Super League Enterprise With Buy Rating, $5 Price Target

MT Newswires Live

Super League Enterprise Initiated at Buy by Aegis Capital

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Press Release: Super League Advances Digital Asset Strategy Following Completion of Financing Backed by Evo Fund

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

BRIEF-Super League Regains Full Compliance With Nasdaq Listing Requirements

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":3.7,"timestamp":1774641600000,"preClose":4.17,"halted":0,"volume":46103,"hourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.7,"latestTime":"19:55 EDT","volume":335,"amount":1262.45,"timestamp":1774655759045,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.1127098321342925,"floatShares":697356,"shares":968600,"eps":-190.75543,"marketStatus":"Market Closed","change":-0.47,"latestTime":"03-27 16:00:00 EDT","open":4.28,"high":4.3461,"low":3.5,"amount":175972.3755994,"amplitude":0.202902,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-190.75543,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":4.17,"preHourTrading":{"tag":"盘前","latestPrice":4.31,"preClose":4.16,"latestTime":"09:12 EDT","volume":1822,"amount":7998.0375906,"timestamp":1774617126985,"change":0.15,"changeRate":0.036058,"amplitude":0.101298},"postHourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.7,"latestTime":"19:55 EDT","volume":335,"amount":1262.45,"timestamp":1774655759045,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.148643},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":697356,"roa":"-85.59%","roe":"-2095.51%","lyrEps":-1128.603888,"volumeRatio":2.148643,"shares":968600,"dividePrice":0,"high":4.3461,"amplitude":0.202902,"preClose":4.17,"low":3.5,"week52Low":3.25,"pbRate":"-1.78","psRate":"0.31","week52High":196.8,"institutionHeld":0,"latestPrice":3.7,"eps":-190.75543,"divideRate":0,"volume":46103,"delay":0,"ttmEps":-190.75543,"open":4.28,"prevYearClose":7.326,"prevWeekClose":4.7,"prevMonthClose":3.97,"prevQuarterClose":7.326,"fiveDayClose":4.7,"twentyDayClose":3.97,"sixtyDayClose":6.7536},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"SLE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":-3.12,"defaultRemindTime":1774598400000,"name":null,"time":"Pre-Market","dateTimestamp":1774584000000,"actualEps":null},{"market":"US","date":"2026-01-23","symbol":"SLE","defaultRemindTime":1769178600000,"type":"split","dateTimestamp":1769144400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-11-13","symbol":"SLE","fiscalQuarterEnding":"2025/09","expectedEps":-2.83,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-2.3},{"market":"US","date":"2025-08-14","symbol":"SLE","fiscalQuarterEnding":"2025/06","expectedEps":-6.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-4.52},{"market":"US","date":"2025-06-23","symbol":"SLE","defaultRemindTime":1750685400000,"type":"split","dateTimestamp":1750651200000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1762833600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2026-03-26","current":-0.019397,"percent":0.646481,"low":-0.738945,"twenty":-0.359366,"median":-0.271962,"eighty":-0.210302,"high":-0.044016,"avg":-0.284123,"sd":0.119248,"marketCap":3777450},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959},{"date":"2025-08-15","current":-0.231876,"twenty":-0.33606,"median":-0.271353,"eighty":-0.213354,"marketCap":3618418},{"date":"2025-08-22","current":-0.221928,"twenty":-0.335323,"median":-0.269787,"eighty":-0.212104,"marketCap":3535981},{"date":"2025-08-29","current":-0.23749,"twenty":-0.333566,"median":-0.269388,"eighty":-0.213354,"marketCap":3783930},{"date":"2025-09-05","current":-0.192157,"twenty":-0.332345,"median":-0.269014,"eighty":-0.213084,"marketCap":3061642},{"date":"2025-09-12","current":-0.207719,"twenty":-0.332042,"median":-0.268116,"eighty":-0.210012,"marketCap":3309592},{"date":"2025-09-19","current":-0.247639,"twenty":-0.331721,"median":-0.267958,"eighty":-0.20982,"marketCap":3945637},{"date":"2025-09-26","current":-0.362878,"twenty":-0.332345,"median":-0.267958,"eighty":-0.210012,"marketCap":5781732},{"date":"2025-10-03","current":-0.272683,"twenty":-0.334082,"median":-0.268394,"eighty":-0.210038,"marketCap":4344654},{"date":"2025-10-10","current":-0.24891,"twenty":-0.332345,"median":-0.268116,"eighty":-0.210567,"marketCap":3965889},{"date":"2025-10-17","current":-0.321134,"twenty":-0.33627,"median":-0.269014,"eighty":-0.211856,"marketCap":5116629},{"date":"2025-10-24","current":-0.188157,"twenty":-0.335429,"median":-0.268704,"eighty":-0.211856,"marketCap":2997912},{"date":"2025-10-31","current":-0.131167,"twenty":-0.334082,"median":-0.267958,"eighty":-0.20982,"marketCap":2089890},{"date":"2025-11-07","current":-0.105839,"twenty":-0.332345,"median":-0.267719,"eighty":-0.208727,"marketCap":1686325},{"date":"2025-11-14","current":-0.110362,"twenty":-0.332042,"median":-0.267321,"eighty":-0.207583,"marketCap":1758390},{"date":"2025-11-21","current":-0.081028,"twenty":-0.331721,"median":-0.26512,"eighty":-0.206427,"marketCap":1285354},{"date":"2025-11-28","current":-0.659255,"twenty":-0.334597,"median":-0.266863,"eighty":-0.206708,"marketCap":10457765},{"date":"2025-12-05","current":-0.720254,"twenty":-0.337177,"median":-0.26748,"eighty":-0.207472,"marketCap":11425396},{"date":"2025-12-12","current":-0.614194,"twenty":-0.34219,"median":-0.267958,"eighty":-0.207492,"marketCap":9742959},{"date":"2025-12-19","current":-0.474574,"twenty":-0.347254,"median":-0.268394,"eighty":-0.207537,"marketCap":7528174},{"date":"2025-12-26","current":-0.4608,"twenty":-0.349022,"median":-0.269014,"eighty":-0.207719,"marketCap":7309663},{"date":"2026-01-02","current":-0.447318,"twenty":-0.351152,"median":-0.26966,"eighty":-0.207719,"marketCap":7095801},{"date":"2026-01-09","current":-0.503223,"twenty":-0.354793,"median":-0.269873,"eighty":-0.208261,"marketCap":7982631},{"date":"2026-01-16","current":-0.526743,"twenty":-0.360917,"median":-0.271353,"eighty":-0.208641,"marketCap":8355727},{"date":"2026-01-23","current":-0.388481,"twenty":-0.368101,"median":-0.272683,"eighty":-0.20874,"marketCap":6162476},{"date":"2026-01-30","current":-0.377954,"twenty":-0.369864,"median":-0.273838,"eighty":-0.208765,"marketCap":5995491},{"date":"2026-02-06","current":-0.254616,"twenty":-0.369341,"median":-0.274166,"eighty":-0.209154,"marketCap":4038966},{"date":"2026-02-13","current":-0.250952,"twenty":-0.368944,"median":-0.274262,"eighty":-0.209588,"marketCap":3980851},{"date":"2026-02-20","current":-0.244846,"twenty":-0.368353,"median":-0.273838,"eighty":-0.20982,"marketCap":3883993},{"date":"2026-02-27","current":-0.219812,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"marketCap":3486877},{"date":"2026-03-06","current":-0.285756,"twenty":-0.365648,"median":-0.271783,"eighty":-0.20982,"marketCap":4532940},{"date":"2026-03-13","current":-0.266522,"twenty":-0.361898,"median":-0.272212,"eighty":-0.210012,"marketCap":4227838},{"date":"2026-03-20","current":-0.285756,"twenty":-0.360355,"median":-0.272267,"eighty":-0.210038,"marketCap":4532940},{"date":"2026-03-26","current":-0.23813,"twenty":-0.359366,"median":-0.271962,"eighty":-0.210302,"marketCap":3777450}],"updateTime":1774664313429},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584971876","title":"Super League Enterprise Raises $20 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2584971876","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584971876?lang=en_us&edition=fundamental","pubTime":"2025-11-20 06:30","pubTimestamp":1763591427,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc. announced the completion of a $20 million private placement, which has contributed to strengthening the company's balance sheet and eliminating its debt. The financing round was led by Evo Fund, which committed $10 million. The company stated that this capital raise, along with recent corporate restructuring, positions Super League to pursue new growth opportunities, including potential strategies within the digital asset economy and accretive mergers and acquisitions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securiti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL8rcdCP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2584058526","title":"Super League Enterprise Inc. Publishes Transcript of Third Quarter 2025 Earnings Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2584058526","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584058526?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:25","pubTimestamp":1763425500,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc. has published the transcript of its Third Quarter 2025 Earnings Conference Call, which took place on November 13, 2025. The event was attended by company management, including the President and Chief Executive Officer, as well as representatives from Maxim Group and Taglich Brothers. During the call, management discussed the company's recent progress and strategic outlook. They highlighted that Super League is \"in a stronger position to succeed now than at any point since pivoting our business into the gaming media space four years ago.\" The CEO noted that the company recently secured $20 million in financing, stating, \"We are fully funded with no plans to go back to market other than for opportunistic growth.\" Management emphasized a focus on scaling operations, recapturing revenue momentum, and pursuing new business opportunities, following what they described as a \"structural turnaround that sets the stage for lasting growth and renewed value creation fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL8zPQD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2583685787","title":"Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2583685787","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583685787?lang=en_us&edition=fundamental","pubTime":"2025-11-15 02:02","pubTimestamp":1763143320,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics, Inc.  on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus .SLE is a chronic autoimmune disease where the body’s immune system attacks healthy tissues and organs, causing inflammation in various parts of the body, including joints, skin, kidneys, and the brain.Initial data reported a significant reduction in disease activity following initial Descartes-08 treatment, with 100% of participants who reached Month 3 follow-up (n=3) achieving Lupus Low Disease Activity State response.Disease remission was seen in 2 out of 3 participants at Month 3.At this time, Cartesian plans to pause further development of Descartes-08 in SLE, including enrollment in the Phase 2 trial, to prioritize the opportunities in myasthenia gravis, currently in Phase 3, and myositis.Cartesian announced the planned expansion of Descartes-08 into myositis.In this trial, no significant adverse e","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/14/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/14/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4077","SLE","BK4139","RNAC"],"gpt_icon":0},{"id":"2583512496","title":"Super League Enterprise Q3 Adj. EPS $(2.52) Beats $(2.79) Estimate, Sales $2.423M Miss $3.395M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512496","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512496?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:31","pubTimestamp":1763069472,"startTime":"0","endTime":"0","summary":"Super League Enterprise (NASDAQ:SLE) reported quarterly losses of $(2.52) per share which beat the analyst consensus estimate of $(2.79) by 9.84 percent. This is a 75.27 percent increase over losses of $(10.19) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851305/super-league-enterprise-q3-adj-eps-2-52-beats-2-79-estimate-sales-2-423m-miss-3-395m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Super League Enterprise Q3 Adj. EPS $(2.52) Beats $(2.79) Estimate, Sales $2.423M Miss $3.395M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2583512433","title":"Super League Enterprise Reports Financial Turnaround and Restores Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512433","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512433?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:30","pubTimestamp":1763069419,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc. announced its third quarter 2025 financial results, highlighting a pivotal financial turnaround for the company. The company reported it has completed a series of capital and balance-sheet transactions, including a $20 million private placement, resulting in its strongest balance sheet in several years and eliminating all debt. Super League stated that these actions have restored full Nasdaq compliance across all listing requirements. The company emphasized continued revenue diversification and maintenance of a lean cost structure, outlining a clear path to profitability and growth. Super League also noted ongoing partnerships with brands such as Google, Panda Express, Lionsgate, and Bazooka Brands, and indicated plans to explore new business avenues, including accretive mergers and acquisitions and potential expansion into the digital asset economy. The company stated it is positioned for disciplined, sustainable growth into 2026 and beyond.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL6025kK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1046421795.USD","LU2491050071.SGD","LU0345774631.USD","LU1066053197.SGD","NDAQ","LU0466842654.USD","LU1267930730.SGD","LU0648001328.SGD","LU1221951046.USD","LU1974910355.USD","LU0097036916.USD","IE0004086264.USD","LU0345774391.USD","LU1221951129.SGD","LU1366192091.USD","SGXZ31699556.SGD","LU0109391861.USD","LU2065170008.USD","LU2362541273.HKD","LU2125154935.USD","LU0661504455.SGD","LU0889566641.SGD","LU2362541513.USD","LU0310800965.SGD","LU2357305700.SGD","LU0985320562.USD","BK4534","LU0784384876.USD","LU0310799852.SGD","LU2028103732.USD","LION","LU1059921491.USD","SLE","BK4538","LU0980610538.SGD","LU1196500208.SGD","LU1366333091.USD","LU0868494617.USD","BK4533","LU0528227936.USD","LU0342679015.USD","LU1880398471.USD","LU2491050154.USD","LU2087621335.USD","LU2491049909.HKD","LU0107464264.USD","LU1670628061.USD","LU0545039389.USD","LU2417539215.USD"],"gpt_icon":1},{"id":"2583512498","title":"Super League Enterprise Inc - Q3 Revenues Decline to $2.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512498?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:30","pubTimestamp":1763069401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUAW4D0R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2583548181","title":"Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583548181","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583548181?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068500,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  13, 2025  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187873/0/en/Alumis-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007","BK4077","LU2065732104.USD","SLE","BK4097","PRGS"],"gpt_icon":0},{"id":"2583951452","title":"Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2583951452","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583951452?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067900,"startTime":"0","endTime":"0","summary":"100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187838/0/en/Cartesian-Therapeutics-Announces-Strong-Efficacy-Signal-in-Phase-2-Trial-of-Descartes-08-in-Patients-with-SLE-and-Expansion-of-Clinical-Development-into-Myositis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","IE0031619046.USD","IE0009354923.USD","MG","BK4023","BK4077","BK4123","IE00B19Z4B17.USD","BK4187","DSGX","SLE","LU2065731478.USD","BK4139","CRS","IE00B7SZL793.SGD","LU0963586101.USD","IE00B66KJ199.SGD","RNAC"],"gpt_icon":0},{"id":"2583652514","title":"Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583652514","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583652514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067660,"startTime":"0","endTime":"0","summary":"Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187807/0/en/Vor-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4077","SLE","SD","BK4213"],"gpt_icon":0},{"id":"2583966185","title":"Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583966185","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583966185?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040600,"startTime":"0","endTime":"0","summary":"Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187342/24675/en/Fate-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4187","BK4110","BK4006","BK4139","LU2463526074.USD","CAR","FATE","BK4081","EMA","IE0031619046.USD","LU0963586101.USD","IE00B19Z4B17.USD","ACR","LU0456854461.SGD","LU2065731478.USD","CRC","BK4205","BK4233","IIM","BK4109","BK4213","BK4528","ASH","BK4230","BK4022","BK4156","UK","SLE","IE00B7SZL793.SGD","LU0266512127.USD","CRS","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2582872883","title":"CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582872883","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582872883?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779600,"startTime":"0","endTime":"0","summary":"-Positive Phase 1 data for CTX310 presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184507/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","FXI","LU2463526074.USD","KSA","LU1430594728.SGD","BK4597","LU0432979614.USD","CRSP","BK4109","BK4588","LU1674673428.USD","LU2362540622.SGD","CAR","IE00B2B36J28.USD","LU1861559042.SGD","LU0942090050.USD","LDL","LU2456880835.USD","BK4153","LU0417517546.SGD","IE00B19Z3581.USD","LU1585245621.USD","VRTX","LU0079474960.USD","LU1778281490.HKD","BK4230","LU1674673691.USD","IE0009355771.USD","LU2236285917.USD","LU0234570918.USD","LU0963586101.USD","LU0061475181.USD","VERX","BK4149","SCD","IE00BZ9MQY76.HKD","LU2324357040.USD","LU0566484027.USD","CAT","LU2237438978.USD","MACE","LU1559883803.SGD","LU1988902786.USD","TG","ASH","UAE","SLE","LU1035775433.USD","LU1917777945.USD","AHP"],"gpt_icon":0},{"id":"2582344879","title":"Aegis Capital Initiates Coverage on Super League Enterprise With Buy Rating, $5 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2582344879","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582344879?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:57","pubTimestamp":1762779455,"startTime":"0","endTime":"0","summary":"Aegis Capital Initiates Coverage on Super League Enterprise With Buy Rating, $5 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2582909878","title":"Super League Enterprise Initiated at Buy by Aegis Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582909878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582909878?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:45","pubTimestamp":1762775100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 06:45 ET (11:45 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2582865090","title":"Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2582865090","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582865090?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:45","pubTimestamp":1762620300,"startTime":"0","endTime":"0","summary":"Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/08/3184078/0/en/Telitacicept-Achieved-Primary-Endpoint-of-Reducing-Proteinuria-in-Stage-A-of-a-Phase-3-Clinical-Study-for-IgA-Nephropathy-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","LU1223082519.USD","BK4077","SSI","SLE","CDE","LU1223082196.USD","BK4017","LU1223083913.SGD"],"gpt_icon":0},{"id":"2581095232","title":"Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095232","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095232?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:01","pubTimestamp":1762430460,"startTime":"0","endTime":"0","summary":"PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026  Clinical tri","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3182420/0/en/Climb-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443622.USD","IE00BKVL7J92.USD","LU1363072403.SGD","CMC","BK4077","LU0882574139.USD","LU2746668461.USD","LU2237443465.HKD","LU0149725797.USD","LU2237443978.SGD","IE00BHPRN162.USD","IE00BZ1G4Q59.USD","BK4006","BK4199","SLE","ITP","IE00BFXG1179.USD","LU2237443549.SGD","LU0267386448.USD","LU0971096721.USD","LU0170899867.USD","LU2237443382.USD","LU2746668974.SGD","LU2237443895.HKD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2581727740","title":"Press Release: Super League Advances Digital Asset Strategy Following Completion of Financing Backed by Evo Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2581727740","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581727740?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:00","pubTimestamp":1762347600,"startTime":"0","endTime":"0","summary":"Following Recent Evo Fund Financing, Super League Accelerates Execution of Q1 Digital Asset Initiatives. SANTA MONICA, Calif., Nov. 05, 2025  -- Super League  , a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, today announced that, following the successful completion of its financing backed by Evo Fund, the Company is advancing its plans to launch a digital asset strategy in the first quarter of 2026.With this next phase of execution now underway, Super League has:. -- Commenced a search to identify and appoint a digital asset expert to its. Board of Directors, further strengthening the Company's strategic. support the design and execution of its digital asset strategy, targeting. \"Our partnership with Evo Fund has positioned Super League to move decisively into this next frontier of our business,\" said Matt Edelman, Chief Executive Officer of Super League. \"We are accelerating efforts to integrate dig","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","SLE","BK4077"],"gpt_icon":0},{"id":"2580976219","title":"Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580976219","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580976219?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:05","pubTimestamp":1762178700,"startTime":"0","endTime":"0","summary":"LONDON and GAITHERSBURG, Md., Nov.  03, 2025  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179401/0/en/Autolus-Therapeutics-to-Present-Clinical-Data-Updates-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","BK4006","LU2463526074.USD","BK4077","BK4588","LU2355687059.USD","LU2065731478.USD","AFG","LU0963586101.USD","IE00B7SZL793.SGD","BK4022","BK4007","UCL","IE00B66KJ199.SGD","FC","BK4132","LU0985320562.USD","LU1571399168.USD","BK4230","BK4533","BK4107","ASH","BK4585","SLE","LU1699723380.USD","BK4187","LENZ","IE00B19Z4B17.USD","BK4117","BK4123","OS","BK4109","CRS","BK4539","ALL","BK4097","BK4139","CAR"],"gpt_icon":0},{"id":"2579930188","title":"Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2579930188","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579930188?lang=en_us&edition=fundamental","pubTime":"2025-10-29 23:01","pubTimestamp":1761750060,"startTime":"0","endTime":"0","summary":"Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176649/0/en/Telitacicept-Demonstrates-Sustained-Efficacy-and-Favorable-Safety-Profile-in-48-Week-China-Phase-3-Open-Label-Extension-Generalized-Myasthenia-Gravis-Data.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","SLE","BK4077","BK4178","AAN"],"gpt_icon":0},{"id":"2579907486","title":"BRIEF-Super League Regains Full Compliance With Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2579907486","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579907486?lang=en_us&edition=fundamental","pubTime":"2025-10-29 22:33","pubTimestamp":1761748405,"startTime":"0","endTime":"0","summary":"BRIEF-Super League Regains Full Compliance With Nasdaq Listing RequirementsSuper League Enterprise Inc SLE.O:SUPER LEAGUE REGAINS FULL COMPLIANCE WITH NASDAQ LISTING REQUIREMENTSSource text: ID:nGNX38gv3CFurther company coverage: SLE.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA18Z454:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2579900527","title":"Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2579900527","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579900527?lang=en_us&edition=fundamental","pubTime":"2025-10-29 22:30","pubTimestamp":1761748200,"startTime":"0","endTime":"0","summary":"NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1Data showed consistentimprovementsacross secondary outcome measures, and a f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176619/0/en/Novartis-ianalumab-first-drug-to-reduce-disease-activity-and-patient-burden-in-Sj%C3%B6gren-s-disease-Phase-III-trials.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4110","BK4077","SLE","BK4134","III","BK4199","ACR"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":109,"code":"91000000","status":"200"}]}}